查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848738

按成像技術、應用、最終用戶、切片檢查類型和引導系統分類的切片檢查引導系統市場—2025-2032年全球預測

Biopsy Guidance System Market by Imaging Technology, Application, End User, Biopsy Type, Guidance System - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，切片檢查引導系統市場規模將達到 27.8 億美元，複合年成長率為 7.61%。

關鍵市場統計數據
基準年 2024 15.4億美元
預計年份：2025年 16.6億美元
預測年份 2032 27.8億美元
複合年成長率 (%) 7.61%

為切片檢查引導領域提供明確的指導，重點闡述了臨床促進因素、技術推動因素、監管壓力以及相關人員的業務需求。

切片檢查引導生態系已進入創新期，這得益於臨床需求與技術成熟度的整合。臨床醫師要求在最大限度減少患者不適和手術風險的同時，提高診斷準確性，從而提升了先進影像技術和引導平台的重要性。同時，設備製造商和解決方案提供者正致力於整合、互通性和工作流程效率的提升，以縮短手術時間並提高可重複性。這些因素正在重塑醫院、門診中心和診斷機構的採購標準。

在此背景下，相關人員必須應對臨床應用路徑、監管預期和報銷機制之間錯綜複雜的相互作用。提供能夠證明其相對臨床價值的證據日益影響應用決策，支付方也更加關注手術結果和成本動態。因此，產品開發藍圖優先考慮易用性、降低手術操作差異以及與現有影像基礎設施的兼容性。本引言透過揭示定義當前市場發展階段的臨床促進因素、技術推動因素和營運重點，為後續分析奠定了更廣泛的基礎。

機器人技術、多模態成像和軟體智慧領域的創新如何重新定義切片檢查引導的手術精度和臨床價值

切片檢查引導領域正經歷一場變革，機器人技術、影像技術的進步以及軟體智慧的融合，顯著提升了手術的精準度和臨床可靠性。機器人輔助技術正從概念驗證階段走向成熟，逐漸融入常規工作流程，即使在解剖結構複雜的病例中，也能實現高度可重複的穿刺路徑和精準的靶向定位。同時，電腦斷層掃描（CT）和磁振造影）等影像技術不斷提升軟組織對比度和空間解析度，超音波平台也正朝著更先進的2D、3D和多普勒成像方向發展，進一步拓展了照護現場應用的潛力。

此外，即時導航系統和影像融合技術的興起，也為結合各種顯像模式優勢的多模態方法鋪路。軟體主導的決策支持，包括病灶特徵分析和軌跡規劃，正逐漸成為綜合解決方案的必備組成部分。綜合這些變化，價值提案正在重新調整。買家越來越青睞那些能夠減少重複手術、縮短學習曲線並與電子健康記錄整合的系統。隨著應用普及速度的加快，那些優先考慮檢驗的臨床結果和互通生態系統的供應商，將更有利於在各種臨床環境中獲得持續認可。

評估近期美國關稅調整對導引系統採購、供應鏈韌性和產品架構的營運和策略影響。

美國近期關稅政策的變化為切片檢查引導系統的跨境採購和供應鏈規劃帶來了複雜性。關稅調整影響範圍廣泛，涵蓋從影像處理電子元件到精密機械組裝等眾多零件，導致到岸成本變化，促使跨國供應商重新評估籌資策略。為此，許多供應商正在探索近岸外包方案，實現供應商多元化，並調整庫存策略以應對成本的突發波動。這些營運措施旨在保護淨利率，同時確保優先臨床客戶的產品供應。

關稅主導的轉變不僅會影響直接成本，還會影響產品架構和售後服務經濟效益。製造商可能會重新設計模組，以依賴國內採購的子組件，或改變組裝以降低風險。此類重新設計也會影響監管文件和檢驗時間表，因此需要積極主動地進行變更管理。從買方的角度來看，採購負責人在更換供應商時必須考慮更長的交貨時間和潛在的重新驗證工作。總體而言，關稅正在加速策略前置作業時間彈性規劃的製定，並使商業敏捷性成為價值鏈上相關人員的核心競爭力。

將顯像模式、臨床應用、終端用戶環境、切片檢查技術和引導平台與可操作的商業化路徑進行細分洞察

關鍵細分市場動態揭示了臨床需求與技術差異化的交匯點，為有針對性的投資和商業化策略提供了指南。基於影像技術，可分為電腦斷層掃描（CT）、磁振造影（MRI）、立體定位系統、超音波和X光設備，其中超音波可進一步細分為2D超音波、3D超音波和多普勒超音波。基於應用領域，可分為乳房、腎臟、肝臟、肺部、前列腺和甲狀腺等臨床重點領域，每種應用都對影像、穿刺和切片檢查操作提出了獨特的要求，這些要求會影響產品設計和培訓需求。

終端使用者細分將門診手術中心、影像診斷中心、醫院和門診診所確定為主要治療場所，其中醫院進一步分為私人醫院和公立醫院。按切片檢查類型分類，診所區分粗針穿刺活體組織切片和細針穿刺活體組織切片，粗針切片技術又細分為彈簧式和真空輔助式，這些選擇反映了組織產量、手術創傷性和病理處理流程之間的權衡。最後，導航粗針穿刺切片偏好分為手動系統和機器人系統，其採用軌跡取決於對準確性提升、工作流程中斷程度和臨床醫生熟練程度的預期。綜上所述，這些細分凸顯了產品客製化、差異化臨床證據產生以及客製化服務模式的機會，這些模式能夠滿足每種方式、應用、終端用戶和手術的特定需求。

影響美洲、中東和非洲以及亞太地區招募、夥伴關係和商業化策略的區域動態和商業路徑

區域動態影響技術的普及速度、報銷框架和夥伴關係生態系統，理解這些細微差別對於有效的市場進入和規模擴大策略至關重要。在美洲，需求模式受到支付方格局的異質性和臨床創新中心集中化的影響，這些因素推動了先進指導平台的早期應用。採購決策通常受臨床證據和醫院系統優先事項的影響，而門診中心則越來越傾向於尋求具成本效益、高通量的解決方案。在歐洲、中東和非洲，監管的多樣性和基礎設施成熟度的差異導致了不同的普及曲線，中心三級醫院通常作為先進可攜式的樞紐，而偏遠和資源匱乏的地區則優先考慮經濟高效、攜帶式治療方法。

亞太地區醫療體系的快速現代化和龐大的患者數量，既為規模化發展創造了機遇，也催生了在地化商業化策略的必要性。區域人才庫、本地製造獎勵以及經銷夥伴，都會進一步影響企業如何部署培訓、服務模式和售後支援。透過將產品價值提案與區域臨床需求和採購實際情況相結合，相關人員可以最佳化其市場推廣順序和夥伴關係選擇，從而最大限度地提高臨床影響力和商業性轉換率。

競爭格局為買家帶來臨床證據、可互通的生態系統、模組化產品策略和全面的生命週期支援。

切片檢查引導領域的競爭動態主要圍繞著那些能夠成功將硬體可靠性、競爭優勢軟體和卓越服務融為一體，形成完整價值提案的公司。主要企業透過持續投資於臨床證據、法規遵循和互通性來脫穎而出，從而促進與醫院資訊系統和影像檔案庫的整合。提供模組化設計的產品生態系統，例如支援從手動引導擴展到機器人引導以及升級成像模組，往往更能吸引那些優先考慮未來發展前景和整體擁有成本的買家。

此外，提供全面培訓、遠端支援和預測性維護能力的公司可以降低流程差異，並提高客戶維繫。設備製造商、軟體供應商和臨床中心之間的策略夥伴關係能夠促進使用者社群的形成，從而產生真實世界證據並加速最佳實踐的推廣。新參與企業面臨臨床檢驗和服務連續性的高期望，而現有企業則必須透過不斷改善使用者體驗和展示可衡量的結果來防止產品同質化。因此，競爭優勢將越來越依賴臨床可靠性、整合能力和完善的售後服務的結合。

領導者需採取切實可行的策略重點，以落實產品開發、證據收集、供應鏈韌性以及商業性差異化服務模式。

產業領導者應優先採取一系列行動，將市場情報轉化為永續的商業性優勢和臨床應用。首先，產品開發應與特定治療方式的性能要求和最終用戶的工作流程實際情況相符，投資於能夠減少操作差異並幫助臨床醫生快速熟悉產品的解決方案。其次，在包括乳腺癌、肝癌、肺癌、前列腺癌、腎癌和甲狀腺癌在內的關鍵應用領域建立強大的臨床證據項目，以檢驗相對療效並為有利的採購決策提供支持。第三，透過供應商多元化、評估近岸外包方案以及維持策略性庫存來增強供應鏈韌性，從而降低關稅和物流風險。

同時，我們將透過建立可互通的軟體平台來降低技術應用門檻，這些平台能夠促進影像融合、軌跡規劃以及與電子健康記錄的無縫整合。我們將開發滿足醫院、門診手術中心、影像診斷中心和門診診所個人化需求的商業模式，提供靈活的資金籌措和配套服務協議，以緩解資金壓力。最後，我們將投資於培訓、遠端支援和預測性維護，以減少停機時間並增強臨床醫生的信心。持續推動這些措施將改善臨床療效，加速技術應用，並加強與醫療系統和診斷服務提供者的長期夥伴關係。

一種透明的、以臨床醫生為中心的調查方法，結合了主要相關人員的參與、監管檢驗和情景分析，以支持可操作的見解。

本研究結合了對臨床醫生、採購專業人員和行業高管的訪談，並廣泛查閱了監管指南、臨床文獻和產品規格，以確保獲得以臨床醫生為中心的可靠見解。資料收集強調跨職能觀點，以捕捉臨床工作流程、培訓需求和採購決策標準；分析方法結合了定性主題分析和產品功能及服務提供的結構化比較評估。這種方法有意優先考慮三角驗證，以協調不同相關人員的觀點，並揭示對商業化和臨床應用具有實際意義的內容。

品質保證措施包括對照監管文件和同行評審的臨床研究檢驗技術聲明，以及與專家進行迭代審查以完善解讀。在適用情況下，對供應鏈和營運場景進行敏感度測試，以評估不同關稅和物流條件下的韌性。調查方法旨在做到透明和可重複，從而增強相關人員對研究結果的信心，並支持進行有針對性的後續分析，以解決特定的臨床或商業問題。

整合臨床、技術和商業性需求，為切片檢查引導系統的應用和領先地位制定發展路徑

總之，切片檢查引導領域正從漸進式改善邁向一體化創新階段，影像技術、機器人輔助技術和智慧軟體的進步正在融合，重新定義手術標準。儘管臨床上對更高精準度和更輕患者負擔的需求推動了技術的普及，但採購選擇越來越受到臨床價值、互通性和服務連續性等因素的影響。關稅和供應鏈動態進一步增加了策略複雜性，促使製造商和採購商優先考慮技術的韌性和靈活性。

對於相關人員，未來的發展方向在於將技術開發與具體應用需求相結合，投資於嚴格的臨床檢驗，並提供能夠反映不同終端使用者和區域實際情況的客製化商業和服務模式。能夠成功將臨床可靠性、營運可靠性和靈活部署模式相結合的主要企業，將引領技術應用，並創造永續的競爭優勢。產業正蓄勢待發，即將迎來顛覆性變革，而及時做出的策略選擇將決定誰能在技術從專業領域走向主流臨床應用的過程中佔據領導地位。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧驅動的自動病灶檢測和即時回饋整合到切片檢查引導系統中
  • 門診臨床環境中機器人切片檢查導航平台的應用日益增多
  • 可攜式照護現場超音波導引系統在微創切片檢查中的應用
  • 將包括磁振造影、電腦斷層掃描和超音波在內的多重模式影像融合技術整合到精準切片檢查程序中
  • 利用電磁和光纖感測器開發針頭追蹤技術，以實現精準切片檢查定位。
  • 擴大報銷範圍和監管核准將推動先進切片檢查引導設備的應用。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章切片檢查引導系統市場影像技術

  • 電腦斷層掃描
  • 磁振造影
  • 立體定位放射治療
  • 超音波
    • 2D超音波
    • 3D超音波
    • 多普勒超音波
  • X光

第9章 按應用分類的切片檢查引導系統市場

  • 胸部
  • 腎
  • 肝
  • 肺
  • 攝護腺
  • 甲狀腺

第10章 依最終用戶分類的切片檢查引導系統市場

  • 門診手術中心
  • 診斷影像中心
  • 醫院
    • 私立醫院
    • 公立醫院
  • 門診部

第11章 依切片檢查類型分類的切片檢查引導系統市場

  • 核心針穿刺切片
    • 彈簧式
    • 真空輔助
  • 細針穿刺法

第12章切片檢查引導系統市場引導系統

  • 手動的
  • 機器人輔助

第13章 各地區切片檢查引導系統市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章切片檢查引導系統市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國切片檢查引導系統市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GE HealthCare Technologies Inc.
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Hologic, Inc.
    • Canon Medical Systems Corporation
    • Medtronic plc
    • FUJIFILM Holdings Corporation
    • Hitachi, Ltd.
    • Samsung Medison Co., Ltd.
    • Esaote SpA
Product Code: MRR-C271879142B5

The Biopsy Guidance System Market is projected to grow by USD 2.78 billion at a CAGR of 7.61% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.54 billion
Estimated Year [2025] USD 1.66 billion
Forecast Year [2032] USD 2.78 billion
CAGR (%) 7.61%

A definitive orientation to the biopsy guidance landscape that frames clinical drivers, technology enablers, regulatory pressures, and operational imperatives for stakeholders

The biopsy guidance ecosystem has entered a period of accelerated innovation driven by converging clinical imperatives and technology maturation. Clinicians seek higher diagnostic accuracy while minimizing patient discomfort and procedural risk, which has elevated the importance of advanced imaging modalities and guidance platforms. Simultaneously, device manufacturers and solution providers are focusing on integration, interoperability, and workflow efficiencies that reduce procedure time and enhance reproducibility. These forces are reshaping procurement criteria across hospitals, ambulatory centers, and diagnostic facilities.

Against this backdrop, stakeholders must navigate a complex interplay of clinical adoption pathways, regulatory expectations, and reimbursement dynamics. Evidence generation that demonstrates comparative clinical value increasingly influences adoption decisions, and payers are scrutinizing procedure outcomes and cost-effectiveness. As a result, product development roadmaps prioritize ease of use, reduced procedural variability, and compatibility with existing imaging infrastructure. This introduction frames the broader context for subsequent analysis by highlighting the clinical drivers, technology enablers, and operational priorities that are defining the current phase of market evolution.

How converging innovations in robotics, multimodal imaging, and software intelligence are redefining procedural precision and clinical value in biopsy guidance

The landscape for biopsy guidance is experiencing transformative shifts as robotics, imaging refinement, and software intelligence converge to elevate procedural precision and clinical confidence. Robotic assistance is moving beyond proof of concept toward integration in routine workflows, enabling reproducible trajectories and enhanced targeting in anatomically challenging cases. Concurrently, imaging technologies such as computed tomography and magnetic resonance imaging are delivering finer soft tissue contrast and spatial resolution, while ultrasound platforms are diversifying into advanced two dimensional, three dimensional, and Doppler capabilities that expand point-of-care applicability.

Moreover, the rise of real-time navigation systems and image fusion is smoothing the path for multimodal approaches that combine the strengths of each imaging modality. Software-driven decision support, including lesion characterization and trajectory planning, is becoming an expected component of comprehensive solutions. Taken together, these shifts are recalibrating value propositions: purchasers increasingly reward systems that reduce repeat procedures, shorten learning curves, and integrate with electronic medical records. As adoption accelerates, suppliers who prioritize validated clinical outcomes and interoperable ecosystems will be best positioned to capture sustained preference across varied clinical settings.

Assessing the operational and strategic consequences of recent United States tariff shifts on procurement, supply chain resilience, and product architecture for guidance systems

Recent tariff developments in the United States have introduced increased complexity into cross-border procurement and supply chain planning for biopsy guidance systems. Tariff adjustments affect components ranging from imaging electronics to precision mechanical assemblies, altering landed costs and prompting multinational vendors to reassess sourcing strategies. In response, many suppliers are evaluating nearshoring options, diversifying supplier bases, and adjusting inventory policies to buffer against sudden cost fluctuations. These operational moves aim to preserve margin while maintaining product availability for high-priority clinical customers.

Beyond direct cost implications, tariff-driven shifts can influence product architecture and aftersales economics. Manufacturers may redesign modules to rely on domestically sourced subcomponents or alter assembly footprints to mitigate exposure. Such redesign efforts have downstream effects on regulatory documentation and validation timelines, necessitating proactive change management. From a buyer perspective, procurement officers need to account for longer lead times and potential requalification activities when switching suppliers. Overall, tariffs are accelerating strategic supply chain resilience planning and making commercial agility a core competency for stakeholders across the value chain.

Segmentation insights that map imaging modalities, clinical applications, end-user settings, biopsy techniques, and guidance platforms into actionable commercialization pathways

Key segmentation dynamics reveal where clinical demand and technological differentiation intersect, offering guidance for targeted investment and commercialization strategies. Based on imaging technology, the market spans computed tomography, magnetic resonance imaging, stereotactic systems, ultrasound, and X ray equipment, with ultrasound further differentiated into two dimensional ultrasound, three dimensional ultrasound, and Doppler ultrasound; each modality carries distinct strengths for tissue contrast, accessibility, and procedural context, shaping device integration priorities. Based on application, clinical focus areas encompass breast, kidney, liver, lung, prostate, and thyroid procedures, and each application imposes unique imaging, needle access, and biopsy handling requirements that influence product design and training needs.

End-user segmentation identifies ambulatory surgical centers, diagnostic imaging centers, hospitals, and outpatient clinics as primary care settings, with hospitals further split into private and public institutions; these distinctions matter because procurement cycles, capital availability, and clinical governance vary substantially across settings. Based on biopsy type, practices differentiate between core needle biopsy and fine needle aspiration, while core needle approaches subdivide into spring loaded and vacuum assisted mechanisms; the choice among these reflects tradeoffs between tissue yield, procedural invasiveness, and pathology processing workflows. Finally, guidance system preferences fall across manual and robotic assisted platforms, and adoption trajectories depend on perceived gains in accuracy, workflow disruption, and clinician proficiency. Collectively, these segmentation lenses highlight opportunities for product tailoring, differentiated clinical evidence generation, and customized service models that address the specific needs of each modality, application, end user, and procedural technique.

Regional dynamics and operational pathways across the Americas, Europe Middle East and Africa, and Asia Pacific that influence adoption, partnerships, and commercialization strategies

Regional dynamics shape adoption speed, reimbursement frameworks, and partnership ecosystems, and understanding these nuances is essential for effective market entry and scale strategies. In the Americas, demand patterns are influenced by heterogeneous payer landscapes and concentrated centers of clinical innovation that drive early adoption of advanced guidance platforms; procurement decisions are often shaped by clinical evidence and hospital system priorities, while ambulatory centers increasingly seek cost-effective, high-throughput solutions. In Europe, Middle East & Africa, regulatory diversity and variable infrastructure maturity lead to differentiated adoption curves where centralized tertiary hospitals frequently act as hubs for sophisticated technologies, while remote and resource-constrained settings prioritize cost-effective, portable modalities.

Across Asia-Pacific, a mix of rapidly modernizing healthcare systems and large patient volumes creates both scale opportunities and the need for localized commercialization strategies; demand often favors adaptable solutions that align with diverse clinical workflows and varying levels of imaging infrastructure. Regional talent pools, local manufacturing incentives, and distribution partnerships further influence how companies deploy training, service models, and aftermarket support. By aligning product value propositions with regional clinical imperatives and procurement realities, stakeholders can optimize market entry sequencing and partnership selection to maximize clinical impact and commercial uptake.

Competitive company dynamics that reward clinical evidence, interoperable ecosystems, modular product strategies, and comprehensive lifecycle support for buyers

Competitive dynamics within the biopsy guidance arena center on firms that successfully blend hardware reliability, software intelligence, and service excellence into a coherent value proposition. Leading companies differentiate through sustained investment in clinical evidence, regulatory stewardship, and interoperability that eases integration with hospital information systems and imaging archives. Product ecosystems that offer modularity-allowing facilities to scale from manual to robotic assisted guidance or to upgrade imaging modules-tend to resonate with purchasers who prioritize future-proofing and total cost of ownership.

Additionally, companies that provide comprehensive training, remote support, and predictive maintenance capabilities can reduce procedural variability and enhance customer retention. Strategic partnerships between device makers, software vendors, and clinical centers generate real-world evidence and foster user communities that accelerate best-practice dissemination. New entrants face high expectations around clinical validation and service continuity, while incumbents must guard against commoditization by continuously enhancing user experience and demonstrating measurable outcomes. Hence, competitive advantage increasingly derives from a combination of clinical credibility, integration capability, and aftersales service depth.

Actionable strategic priorities for leaders to align product development, evidence generation, supply chain resilience, and commercially differentiated service models

Industry leaders should pursue a prioritized set of actions that translate market intelligence into sustained commercial advantage and clinical adoption. First, align product development with modality-specific performance requirements and end-user workflow realities, investing in solutions that reduce procedural variability and support rapid clinician proficiency. Second, build robust clinical evidence programs across key applications such as breast, liver, lung, prostate, kidney, and thyroid to validate comparative benefits and support favorable procurement decisions. Third, strengthen supply chain resilience by diversifying suppliers, evaluating nearshoring options, and maintaining strategic inventories to mitigate tariff and logistics risks.

In parallel, cultivate interoperable software platforms that facilitate image fusion, trajectory planning, and seamless integration with electronic health records to lower adoption barriers. Develop tailored commercial models that address the distinct needs of hospitals, ambulatory surgical centers, diagnostic imaging centers, and outpatient clinics, and offer flexible financing or bundled service agreements to ease capital constraints. Finally, invest in training, remote support, and predictive maintenance to reduce downtime and enhance clinician confidence. Executed coherently, these actions will improve clinical outcomes, accelerate adoption, and strengthen long-term partnerships with health systems and diagnostic providers.

A transparent and clinician centered research methodology combining primary stakeholder engagement, regulatory validation, and scenario analysis to underpin practical insights

This research synthesizes primary interviews with clinicians, procurement professionals, and industry executives alongside an extensive review of regulatory guidance, clinical literature, and product specifications to ensure robust, clinician-centric insights. Data collection emphasized cross-functional perspectives to capture clinical workflows, training requirements, and procurement decision criteria, and analytic methods integrated qualitative thematic analysis with structured comparative assessments of product capabilities and service offerings. The approach intentionally prioritized triangulation to reconcile divergent stakeholder perspectives and to surface pragmatic implications for commercialization and clinical adoption.

Quality assurance measures included validation of technical claims against regulatory filings and peer-reviewed clinical studies, as well as iterative review cycles with domain experts to refine interpretations. Where applicable, sensitivity testing was applied to supply chain and operational scenarios to assess resilience under different tariff and logistics conditions. The methodology is designed to be transparent and reproducible, providing stakeholders with confidence in the findings and enabling targeted follow-up analyses to address specific clinical or commercial questions.

Synthesis of clinical, technological, and commercial imperatives that define the pathway to wider adoption and leadership in biopsy guidance systems

In conclusion, the biopsy guidance field is transitioning from incremental improvements toward a phase of integrative innovation where imaging evolution, robotic assistance, and smart software converge to redefine procedural standards. Clinical demand for higher accuracy and reduced patient burden is catalyzing adoption, while procurement choices are increasingly shaped by evidence of clinical value, interoperability, and service continuity. Tariff and supply chain dynamics add another layer of strategic complexity, prompting manufacturers and purchasers to prioritize resilience and agility.

For stakeholders, the path forward involves aligning technology development with specific application needs, investing in rigorous clinical validation, and delivering tailored commercial and service models that reflect the realities of diverse end users and regions. Companies that successfully marry clinical credibility with operational reliability and flexible deployment models will lead adoption and create durable competitive positions. The industry is poised for impactful advances, and timely strategic choices will determine who captures leadership as technologies move from specialized settings into mainstream clinical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven automated lesion detection and real-time feedback in biopsy guidance systems
  • 5.2. Rising adoption of robotic assisted biopsy navigation platforms in outpatient clinical settings
  • 5.3. Emergence of portable point of care ultrasound based guidance systems for minimally invasive biopsies
  • 5.4. Integration of multi modality imaging fusion including MRI CT and ultrasound in precision biopsy procedures
  • 5.5. Development of needle tracking technologies with electromagnetic and fiber optic sensors for accurate biopsy placement
  • 5.6. Expanding reimbursement coverage and regulatory approvals driving wider adoption of advanced biopsy guidance devices

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopsy Guidance System Market, by Imaging Technology

  • 8.1. Computed Tomography
  • 8.2. Magnetic Resonance Imaging
  • 8.3. Stereotactic
  • 8.4. Ultrasound
    • 8.4.1. 2D Ultrasound
    • 8.4.2. 3D Ultrasound
    • 8.4.3. Doppler Ultrasound
  • 8.5. X Ray

9. Biopsy Guidance System Market, by Application

  • 9.1. Breast
  • 9.2. Kidney
  • 9.3. Liver
  • 9.4. Lung
  • 9.5. Prostate
  • 9.6. Thyroid

10. Biopsy Guidance System Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Diagnostic Imaging Centers
  • 10.3. Hospitals
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals
  • 10.4. Outpatient Clinics

11. Biopsy Guidance System Market, by Biopsy Type

  • 11.1. Core Needle Biopsy
    • 11.1.1. Spring Loaded
    • 11.1.2. Vacuum Assisted
  • 11.2. Fine Needle Aspiration

12. Biopsy Guidance System Market, by Guidance System

  • 12.1. Manual
  • 12.2. Robotic Assisted

13. Biopsy Guidance System Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biopsy Guidance System Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biopsy Guidance System Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GE HealthCare Technologies Inc.
    • 16.3.2. Siemens Healthineers AG
    • 16.3.3. Koninklijke Philips N.V.
    • 16.3.4. Hologic, Inc.
    • 16.3.5. Canon Medical Systems Corporation
    • 16.3.6. Medtronic plc
    • 16.3.7. FUJIFILM Holdings Corporation
    • 16.3.8. Hitachi, Ltd.
    • 16.3.9. Samsung Medison Co., Ltd.
    • 16.3.10. Esaote S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BIOPSY GUIDANCE SYSTEM MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BIOPSY GUIDANCE SYSTEM MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOPSY GUIDANCE SYSTEM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY STEREOTACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 2D ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY 3D ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DOPPLER ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY X RAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BREAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PROSTATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY THYROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SPRING LOADED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ROBOTIC ASSISTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY CORE NEEDLE BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY GUIDANCE SYSTEM, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY IMAGING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY BIOPSY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC BIOPSY GUIDANCE SYSTEM MARKET SIZE, BY